|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
3/2013
vol. 115 abstract:
Case report
Unilateral extrafoveal choroidal neovascularization in a 13-year-old child with bilateral optic nerve drusen
Monika Jędrzejczak-Stróżniak
1
,
Joanna Siwiec-Prościńska
1
,
Anna Gotz-Więckowska
1
,
Jarosław Kocięcki
1
Klinika Oczna 2013, 115 (3): 230-233
Online publish date: 2013/09/26
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Aim: The aim of our research was to describe the effect of an off-label intravitreal ranibizumab injection for treatment of unilateral extrafoveal choroidal neovascularization a with bilateral optic nerve drusen.
Material and methods: 13-year-old girl presented with decreased visual acuity of her left eye and optic nerve drusen confirmed by B-scan ultrasound examination in both eyes. Fluorescein angiography and optical coherence tomography revealed the presence of choroidal neovascularization in the left eye. The patient was treated with a single injection of ranibizumab and monitored by clinical examination, optical coherence tomography and fluorescein angiography. Results: Choroidal neovascularization was successfully treated and the best corrected visual acuity (Snellen) fully recovered from 20/50 to 20/20 over a period of 2 months. After this time at the 30 months follow-up, visual acuity and fundus were stable without the recurrence of choroidal neovascularization. Conclusions: Optic nerve drusen should be taken into account and carefully observed as a possible cause of peripapillary choroidal neovascularization in children. Ranibizumab can be a successful off-label treatment in children suffering from choroidal neovascularization associated with optic nerve drusen. keywords:
choroidal neovascularization, optic nerve drusen, ranibizumab |
|
POLSKI
